Literature DB >> 17633002

[Tetanus following intramuscular injection in Dakar: epidemiological, clinical and prognostic features].

C T Ndour1, M Soumare, S D Mbaye, M Seydi, B M Diop, P S Sow.   

Abstract

INTRODUCTION: tetanus stills a major public health problem in developing countries despite the availability of an efficient and accessible vaccine. The aim of this study was to evaluate the epidemiological and clinical pattern and the prognosis of intramuscular injection. PATIENTS AND METHODS: This is a retrospective study from the medical charts of 4 6 patients admitted for tetanus following intramuscular injection in the infectious diseases clinic ward of Fann hospital of Fann, in Dakar, between January 1999 and December 2002.
RESULTS: The prevalence was 10% with a mean of 11.5 cases per year. The mean age was 34.5 years. The substance injected was known in 33 cases. Quinine injection was responsible in 32 cases. The period of onset was shorter than 48 hours in 39 cases (84.8%). The lethality rate was high (60.8%). The prognosis factors were the mean delay before h ospitalisation lower than 3 days (p = 0.03) and a scoring stage more than 4 (P = 0.01).
CONCLUSION: Tetanus following intramuscular injection is usually caused by quinine injection. The effective prevention relies on the training of health care workers and the strict application of the Guidelines of the National Program against Malaria.

Entities:  

Mesh:

Year:  2005        PMID: 17633002

Source DB:  PubMed          Journal:  Dakar Med        ISSN: 0049-1101


  2 in total

1.  Prognosis of tetanus patients in the intensive care unit of Provincial Hospital Jason Sendwe, Lubumbashi, DR Congo.

Authors:  Michel Manika Muteya; Alain Kabey a Kabey; Théophile Muyumba Lubanga; Henri Mundongo Tshamba; Albert Mwembo Tambwe a Nkoy
Journal:  Pan Afr Med J       Date:  2013-03-10

2.  Tetanus disease and deaths in men reveal need for vaccination.

Authors:  Shona Dalal; Julia Samuelson; Jason Reed; Ahmadu Yakubu; Buhle Ncube; Rachel Baggaley
Journal:  Bull World Health Organ       Date:  2016-06-02       Impact factor: 9.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.